ERBB2 and breast carcinoma: To assess the suitability of the lead humanised NM-02 candidate (variant K) for imaging purposes and therefore potential theranostic application, an in vivo biodistribution analysis was performed using orthotopic HER2+ breast cancer BT474 xenograft mice.